Founded to develop regenerative bone medicine, Bone Biologics Corporation (NASDAQ: BBLG) is well-known for its bone graft substitute product – NELL-1. Currently, the company is focusing its development efforts on bone regeneration in spinal fusion while it continues to pursue additional applications. With preclinical trials showing impressive efficacy, investors seem bullish on the technology’s potential. As the company announced its presence in the upcoming H.C. Wainwright BioConnect conference, investors’ anticipation drove a 30.9% increase in the PPS. In light of this, BBLG is quickly becoming one of the most promising biotech stocks under $5.
BBLG Stock News
Capitalizing on the multibillion-dollar spinal fusion market, BBLG’s flagship product – NELL-1 protein – solves an unmet clinical need within the industry. The technology is showing a lot of potential as preclinical studies recently demonstrated spine fusion effectiveness across three different animal species. In light of this, the FDA accepted pilot study data in Australia – a major milestone for BBLG which could be a steps towards a pivotal US study.
On February 10th, BBLG announced its presence at the upcoming H.C. Wainwright BioConnect Virtual Conference – a bullish sign for the company’s growing presence within the industry. This growth comes as no surprise given the company’s ongoing development efforts of its revolutionary technology. The company’s success throughout the years is largely attributed to BBLG’s groundbreaking work with specific strategic partners. These partnerships have allowed the company to build upon unprecedented research involving the NELL-1 protein and have facilitated major progress.
With a potential to replace current rhBMP (recombinant human proteins), NELL-1 recombinant protein technology addresses limitations and provides faster as well as targeted bone regeneration for “hard healers” with an advantageous safety profile. In light of this, the company’s product addresses not only the $3 billion orthobiologics market for spine fusion, but also additional multibillion-dollar opportunities in the trauma and osteoporosis markets.
As of now, BBLG has exclusive global license to its proprietary technology from UCLA – which is protected by over 13 patents covering more than 200 claims. Aside from this, there are 45 peer-reviewed publications that confer additional scientific validation to BBLG’s technology. The U.S. FDA has approved NELL-1 for review as a device-drug combination product with a Premarket Application (PMA) filing.
This ongoing development is largely attributed to BBLG’s solid management – which continues to place great emphasis on operational excellence for years. In fact, BBLG’s CEO Jeffrey Frelick has over 25 years of experience in the medical technology industry. Meanwhile, Chairman Don Hankey is a highly successful entrepreneur well known for founding the Hankey Group as well as operating seven companies across multiple industries.
Besides its prominent management, another reason why BBLG could be one of the best biotech stocks this week is its heavy insider ownership. Chairman Don Hankey owns over 7.6 million of the company’s shares – 7 million of which are owned by Hankey Capital, LLC and another 470 thousand shares of which are issuable upon exercise of warrants. This heavy ownership acts as a demonstration of Hankey’s belief in the company’s growth potential going forward and is a bullish sign for many investors.
@Retro1upArmy is bullish on BBLG’s NELL-1 protein and its growth potential..
Currently, BBLG is trading at $2.19 with an immediate resistance at 2.25 and another resistance at 2.75. The stock also shows a support near 2. Accumulation has been on an upward trend and the RSI is at 42. The MACD is bearish but is approaching a bullish crossover.
Even though the RSI is relatively low, the steady increase accumulation demonstrates investors’ bullish sentiment as they continue to hold on to their shares in anticipation. Given that the stock is trading near its support, investors could find now a good entry point on BBLG ahead of another run-up.
BBLG Stock Forecast
As it continues capitalizing on its cutting edge technology, BBLG could see new highs in 2022. Now that the NELL-1 is under review, investors are bullish FDA approval could be the catalyst to send BBLG on a major run. With this heavy insider ownership, solid management and a portfolio of patents, there are many reasons to lookout for BBLG in the coming months. As these impending catalysts play out, BBLG could be one of the most promising biotech stocks to buy ahead of news from the company.
If you have questions about BBLG stock and where it could be heading next feel free to reach out to us in our free alerts room!
Please visit and read our disclaimer here.